Company / FCF Margin
Spyre Therapeutics, Inc. FCF Margin History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-11276.5%
FY2023
5-year range
-11276.5% / -289.7%
FY2019-FY2023
Trend
-
vs FY2022
Sector context
#134 of 134
Health Care
What the data says
FCF Margin changed -3792% YoY in FY2023, a notable deviation from the 4-year average annual change of -954%.
Based on SEC 10-K filings.
-11276.5% in FY2023 with a 5-year CAGR of -10864.9%.
Declined from -838.9% to -11276.5% over the past 3 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -10437.7pp
- 5-Year Change
- -10864.9pp
- 10-Year Change
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 134This company -11276.5% Sector average -637.8%
▼
-1668.1% below sector average
Key checks
Key Insights
- Currently 10638.7pp below the Health Care sector average.
- Peak fcf margin was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -11276.5% | - |
| FY2022 | - | - |
| FY2021 | -289.7% | +65.5% |
| FY2020 | -838.9% | -73.0% |
| FY2019 | -484.8% | -17.8% |
| FY2018 | -411.7% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026